Sumiko Takao

Sumiko Takao

Auto-generated profile, based on publicly available information

Sumiko Takao

Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2021 in eLife
Verified
Journal Article
Open access
STSumiko Takao
Sumiko Takao
LFLauren Forbes
Lauren Forbes
MUMasahiro Uni
Masahiro Uni
SCShuyuan Cheng
Shuyuan Cheng
JPJose Mario Bello Pineda
Jose Mario Bello Pineda
AKAlex Kentsis
Alex Kentsis
Dysregulated gene expression contributes to most prevalent features in human cancers. Here, we show that most subtypes of acute myeloid leukemia (AML) depend on the aberrant assembly of MYB transcriptional co-activator complex. By rapid and selective peptidomimetic interference with the binding of CBP/P300 to MYB, but not CREB or MLL1, we find that the leukemic functions of MYB are mediated by CBP/P300 co-activation of a distinct set of transcription factor complexes. These MYB complexes assemble aberrantly with LYL1, E2A, C/EBP family members, LMO2, and SATB1. They are organized convergently in genetically diverse subtypes of AML and are at least in part associated with inappropriate transcription factor co-expression. Peptidomimetic remodeling of oncogenic MYB complexes is accompanied by specific proteolysis and dynamic redistribution of CBP/P300 with alternative transcription factors such as RUNX1 to induce myeloid differentiation and apoptosis. Thus, aberrant assembly and sequestration of MYB:CBP/P300 complexes provide a unifying mechanism of oncogenic gene expression in AML. This work establishes a compelling strategy for their pharmacologic reprogramming and therapeutic targeting for diverse leukemias and possibly other human cancers caused by dysregulated gene control.

8 February 2024 in Blood
Verified
Journal Article
Closed access
PDF file
TDTao Dao
Tao Dao
GXGuangyan Xiong
Guangyan Xiong
SMSung Soo Mun
Sung Soo Mun
JMJeremy Meyerberg
Jeremy Meyerberg
TKTatyana Korontsvit
Tatyana Korontsvit
DSDavid A. Scheinberg
David A. Scheinberg
Chimeric antigen receptor T-cell (CAR T) therapy has produced remarkable clinical responses in B-cell neoplasms. However, many challenges limit this class of agents for the treatment of other cancer types, in particular the lack of tumor-selective antigens for solid tumors and other hematological malignancies, such as acute myeloid leukemia (AML), which may be addressed without significant risk of severe toxicities while providing sufficient abundance for efficient tumor suppression. One approach to overcome this hurdle is dual targeting by an antibody–T-cell receptor (AbTCR) and a chimeric costimulatory signaling receptor (CSR) to 2 different antigens, in which both antigens are found together on the cancer cells but not together on normal cells. To explore this proof of concept in AML, we engineered a new T-cell format targeting Wilms tumor 1 protein (WT1) and CD33; both are highly expressed on most AML cells. Using an AbTCR comprising a newly developed TCR-mimic monoclonal antibody against the WT1 RMFPNAPYL (RMF) epitope/HLA-A2 complex, ESK2, and a secondary CSR comprising a single-chain variable fragment directed to CD33 linked to a truncated CD28 costimulatory fragment, this unique platform confers specific T-cell cytotoxicity to the AML cells while sparing healthy hematopoietic cells, including CD33+ myelomonocytic normal cells. These data suggest that this new platform, named AbTCR-CSR, through the combination of a AbTCR CAR and CSR could be an effective strategy to reduce toxicity and improve specificity and clinical outcomes in adoptive T-cell therapy in AML.

3 April 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
STSumiko Takao
Sumiko Takao
VMVictor Morell
Victor Morell
MUMasahiro Uni
Masahiro Uni
ASAlicia Slavit
Alicia Slavit
SRSophia Rha
Sophia Rha
AKAlex Kentsis
Alex Kentsis
Cancer stem cells are essential for initiation and therapy resistance of many cancers, including acute myeloid leukemias (AML). Here, we apply functional genomic profiling to diverse human leukemias, including high-risk MLL- and NUP98-rearranged specimens, using label tracing in vivo. Human leukemia propagation is mediated by a rare quiescent label-retaining cell (LRC) population undetectable by current immunophenotypic markers. AML quiescence is reversible, preserving genetic clonal competition and epigenetic inheritance. LRC quiescence is defined by distinct promoter-centered chromatin and gene expression dynamics controlled by an AP-1/ETS transcription factor network, where JUN is necessary and sufficient for LRC quiescence and associated with persistence and chemotherapy resistance in diverse patients. This enables prospective isolation and manipulation of immunophenotypically-varied leukemia stem cells, establishing the functions of epigenetic plasticity in leukemia development and therapy resistance. These findings offer insights into leukemia stem cell quiescence and the design of therapeutic strategies for their clinical identification and control.

12 April 2005
Verified
Conference Paper
Closed access
STS. Takao
S. Takao
HOH. Ohta
H. Ohta
YYY. Yokokohji
Y. Yokokohji
TYT. Yoshikawa
T. Yoshikawa
In this research, we focused on the degrees-of-freedom for robot foot mechanism. To realize the functions of human locomotion on biped robots, we should know the fundamental aspects of human foot mechanisms through intensive observations of human locomotion. We proposed a novel mechanical shoe with 2-DOF toe parts, which move independently and are able to constrain human foot in various ways. Wearing the mechanical shoes, three subjects were measured on their walking speed, toe joint angles, and center of pressure. They were walking in straight, zigzag and slalom courses. Through these observations, we show that a biped robot with the proposed toe mechanism could potentially walk faster than conventional ones.

1 January 2003 in The Proceedings of JSME annual Conference on Robotics and Mechatronics (Robomec)
Verified
Journal Article
Open access
PDF file
TIT. Ikeda
T. Ikeda
STS. Takao
S. Takao
ZGZ. Gu
Z. Gu
TMT. Mita
T. Mita
本論文では, ワイヤー駆動方式で3次元空間で運動する4足ロボットの開発を行ったので報告する。まず, 歩行・走行の双方を統一的に扱うことのできる制御方式として可変拘束制御を用いた手法を紹介する。また, 提案した設計法を用いてさまざまな歩容を実現する制御則を設計し, 実験により, 設計したロボット機構の妥当性と制御則の有効性を確認を行ったので, 結果を紹介する。

22 September 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
STSumiko Takao
Sumiko Takao
VMVictor Morell
Victor Morell
MUMasahiro Uni
Masahiro Uni
ASAlicia Slavit
Alicia Slavit
SRSophia Rha
Sophia Rha
AKAlex Kentsis
Alex Kentsis
Many human cancers, including acute myeloid leukemia (AML), arise from mutations of stem and progenitor cells. Immunophenotypic profiling has shown that leukemias develop hierarchically, with mutations in leukemia stem cells associated with disease propagation and relapse 1,2 . Although leukemia initiating cells can be enriched using cell surface markers, their frequency tends to be variable and low, obscuring mechanisms and hindering effective therapies 3,4 . To define AML stem cells in human patients, we performed functional genomic profiling of diverse leukemias using label tracing techniques designed to preserve hematopoietic stem cell (HSC) function in vivo. We found that propagation of human AML is mediated by a rare but distinct quiescent label-retaining cell (LRC) population that evades detection by currently known immunophenotypic markers. We show that human AML LRC quiescence is reversible, sparing genetic clonal competition that maintains its epigenetic inheritance. LRC quiescence is defined by distinct promoter-centered chromatin and gene expression dynamics and controlled by a distinct AP-1/ETS transcription factor network, including JUN in particular, which is associated with disease persistence and chemotherapy resistance in diverse patients. These results enable prospective isolation and functional genetic manipulation of immunophenotypically-varied leukemia stem cells in human patient specimens, as well as establish key functions of epigenetic plasticity in leukemia development and therapy resistance. We anticipate that these findings will lead to the elucidation of essential properties of leukemia stem cell quiescence and the design of therapeutic strategies for their clinical identification and control.